<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218110</url>
  </required_header>
  <id_info>
    <org_study_id>ER19/232</org_study_id>
    <nct_id>NCT04218110</nct_id>
  </id_info>
  <brief_title>Preoperative Skin Preparation Study to Evaluate the Antimicrobial Capabilities of Four Test Substances</brief_title>
  <official_title>Preoperative Skin Preparation Study Following ASTM E1173 Methods to Evaluate the Antimicrobial Capabilities of Four Test Substances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professional Disposables International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Professional Disposables International, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative study of antimicrobial effectiveness evaluation of of 26ml Project X, 10.5ml&#xD;
      Project X, 5.1ml Project X and Prevantics Maxi swabstick following ASTM E1173 - Standard test&#xD;
      method for evaluation of preoperative, precatheterization or preinjection skin preparations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Samples are blinded to the Microbiology group, participant, sponsor (1 of 2) and statistician</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bacterial Microflora in the Inguinal Area</measure>
    <time_frame>10 minutes</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bacterial Microflora in the Inguinal Area</measure>
    <time_frame>30 seconds</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Project X 26ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Project X 10.5ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Project X 5.1ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevantics Maxi Swabstick</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic</intervention_name>
    <description>Application of antiseptic drug to the inguinal area of the subjects</description>
    <arm_group_label>Project X 26ml</arm_group_label>
    <other_name>Project X 26ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic</intervention_name>
    <description>Application of antiseptic drug to the inguinal area of the subjects</description>
    <arm_group_label>Project X 10.5ml</arm_group_label>
    <other_name>Project X 10.5ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic</intervention_name>
    <description>Application of antiseptic drug to the inguinal area of the subjects</description>
    <arm_group_label>Project X 5.1ml</arm_group_label>
    <other_name>Project X 5.1ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevantics 3.15 % / 70 % Swabstick</intervention_name>
    <description>Application of antiseptic drug to the inguinal area of the subjects</description>
    <arm_group_label>Prevantics Maxi Swabstick</arm_group_label>
    <other_name>Prevantics Maxi Swabstick</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female at least 18 years of age and of any race&#xD;
&#xD;
          2. In good general health&#xD;
&#xD;
          3. Read, understand and sign the Informed Consent Form (ICF)&#xD;
&#xD;
          4. If female of child-bearing potential, are willing to use an acceptable method of&#xD;
             contraception to prevent pregnancy (i.e. oral contraceptive, intra-uterine device,&#xD;
             diaphragm, condom, abstinence, bilateral tubal ligation, or are in a monogamous&#xD;
             relationship with a partner who has had a vasectomy)&#xD;
&#xD;
          5. Female subjects of child-bearing potential, must have a negative Urine Pregnancy Test&#xD;
             (UPT) on Treatment Day prior to any applications of the study products&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos,&#xD;
             or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds,&#xD;
             or sunbathing during the 14-day washout conditioning period and during the test period&#xD;
&#xD;
          2. Exposure of the test sites to strong detergents, solvents, or other irritants during&#xD;
             the 14-day washout conditioning period and during the test period&#xD;
&#xD;
          3. Wear fabric softener, bug repellent or UV-treated clothing during the 14-day washout&#xD;
             conditioning period and during the test period&#xD;
&#xD;
          4. Receive an irritation score of 1 (any redness, swelling, rash, or dryness present at&#xD;
             any treatment area) for any individual skin condition prior to the Treatment Day&#xD;
             baseline sample collection&#xD;
&#xD;
          5. Use of systemic or topical antibiotic medications, steroid medications (other than for&#xD;
             hormonal contraception or post-menopausal reasons), or any other product known to&#xD;
             affect the normal microbial flora of the skin during the 14-day washout conditioning&#xD;
             period and during the test period&#xD;
&#xD;
          6. Known allergies or sensitivities to vinyl, latex (rubber), alcohols, metals, inks, or&#xD;
             tape adhesives, or to common antibacterial agents found in soaps, lotions, or&#xD;
             ointments, particularly isopropyl alcohol or chlorhexidine gluconate&#xD;
&#xD;
          7. A medical diagnosis of a physical condition, such as a current or recent severe&#xD;
             illness, asthma, diabetes, hepatitis, an organ transplant, mitral valve prolapses,&#xD;
             congenital heart disease, internal prostheses, or any immunocompromised conditions&#xD;
             such as AIDS (or HIV positive)&#xD;
&#xD;
          8. Pregnancy, plans to become pregnant within the washout and test periods of the study,&#xD;
             or nursing a child&#xD;
&#xD;
          9. Any tattoos or scars within 2&quot; (5.08 cm) of the test sites&#xD;
&#xD;
         10. Dermatoses, cuts, lesions, active skin rashes, or breaks or other skin disorders&#xD;
             within 6&quot; on or around the test sites&#xD;
&#xD;
         11. A currently active skin disease or inflammatory skin condition (for example, contact&#xD;
             dermatitis) anywhere on the body that, in the opinion of the Consulting Physician or&#xD;
             PI, would compromise subject safety or study integrity&#xD;
&#xD;
         12. Showering, bathing, or swimming within the 72-hour period prior to sampling for&#xD;
             Treatment Day, and throughout the test period&#xD;
&#xD;
         13. Participation in another clinical study in the past 30 days or current participation&#xD;
             in another clinical study at time of signing informed consent&#xD;
&#xD;
         14. Any medical condition or use of any medications that, in the opinion of the PI, should&#xD;
             preclude participation&#xD;
&#xD;
         15. Unwillingness to fulfill the performance requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rozalia Olsavszky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EUROFINS EVIC PRODUCT TESTING ROMANIA S.R.L</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins EVIC</name>
      <address>
        <city>Bucharest</city>
        <zip>040256</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preventative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04218110/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>328 individual subjects were consented, screened, treated and completed the study. Each subject is able to receive 2 test products (1 on each side of their body).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Project X 26ml</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="P2">
          <title>Project X 10.5ml</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="P3">
          <title>Project X 5.1ml</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="P4">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.&#xD;
Prevantics 3.15 % / 70 % Swabstick: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Participant data is based on the Intent to Treat (ITT) data set.</population>
      <group_list>
        <group group_id="B1">
          <title>Project X 26ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="B2">
          <title>Project X 10.5ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="B3">
          <title>Project X 5.1ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="B4">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within pre-saturated applicator. 5.1ml volume. Single use.&#xD;
Prevantics 3.15 % / 70 % Swabstick: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="83"/>
            <count group_id="B5" value="329"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.76" spread="9.54"/>
                    <measurement group_id="B2" value="54.39" spread="11.70"/>
                    <measurement group_id="B3" value="54.48" spread="10.99"/>
                    <measurement group_id="B4" value="55.06" spread="10.23"/>
                    <measurement group_id="B5" value="54.67" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Refused to Disclose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Combination of 2 or more races (specify)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.49" spread="13.98"/>
                    <measurement group_id="B2" value="73.37" spread="13.84"/>
                    <measurement group_id="B3" value="75.04" spread="16.11"/>
                    <measurement group_id="B4" value="74.98" spread="15.06"/>
                    <measurement group_id="B5" value="74.47" spread="14.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.03" spread="6.56"/>
                    <measurement group_id="B2" value="163.54" spread="7.84"/>
                    <measurement group_id="B3" value="164.65" spread="8.13"/>
                    <measurement group_id="B4" value="164.15" spread="7.85"/>
                    <measurement group_id="B5" value="163.84" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora in the Inguinal Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
        <time_frame>10 minutes</time_frame>
        <population>The Overall Number of Participants Analyzed represents the modified intent to treat (mITT) dataset where the Participant Flow represents the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 10.5ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O4">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.&#xD;
Prevantics 3.15 % / 70 % Swabstick: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora in the Inguinal Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
          <population>The Overall Number of Participants Analyzed represents the modified intent to treat (mITT) dataset where the Participant Flow represents the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.86" spread="1.58"/>
                    <measurement group_id="O2" value="-4.34" spread="1.48"/>
                    <measurement group_id="O3" value="-3.65" spread="1.36"/>
                    <measurement group_id="O4" value="-3.80" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bacterial Microflora in the Inguinal Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
        <time_frame>30 seconds</time_frame>
        <population>The Overall Number of Participants Analyzed represents the modified intent to treat (mITT) dataset where the Participant Flow represents the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 10.5ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
          <group group_id="O4">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate)/70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.&#xD;
Prevantics 3.15 % / 70 % Swabstick: Application of antiseptic drug to the inguinal area of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora in the Inguinal Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention</description>
          <population>The Overall Number of Participants Analyzed represents the modified intent to treat (mITT) dataset where the Participant Flow represents the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.86" spread="1.55"/>
                    <measurement group_id="O2" value="-3.76" spread="1.36"/>
                    <measurement group_id="O3" value="-3.70" spread="1.58"/>
                    <measurement group_id="O4" value="-3.76" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Project X 26ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="E2">
          <title>Project X 10.5ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="E3">
          <title>Project X 5.1ml</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.&#xD;
Isopropyl alcohol &amp; Chlorhexidine Gluconate Antiseptic: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
        <group group_id="E4">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG/70% v/v IPA contained within pre-saturated applicator. 5.1ml volume. Single use.&#xD;
Prevantics 3.15 % / 70 % Swabstick: Application of antiseptic drug to the inguinal area of the subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Adverse Event</sub_title>
                <description>Unexpected, non-serious adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Commercial Manager</name_or_title>
      <organization>Eurofins EVIC</organization>
      <phone>+40 213357090</phone>
      <email>luciachirita@eurofins.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

